i2E Managementi2E Managementi2E Managementi2E Management
  • About
  • Portfolio
  • Team
  • Funds
  • Investor Login

EyeCRO and NeuMedics Announce Collaboration

    Home Entrepreneur EyeCRO and NeuMedics Announce Collaboration
    NextPrevious

    EyeCRO and NeuMedics Announce Collaboration

    By admin | Entrepreneur, News, SeedStep Angels | Comments are Closed | 4 May, 2015 | 0

    Breakthrough eyedrop therapeutic to treat Diabetic Retinopathy.

    Oklahoma City, OK and Seattle, WA (PRWEB) May 04, 2015 — EyeCRO LLC and NeuMedics Inc., today announced the formation of a collaboration to facilitate development of NM108, a first-in-class small molecule to treat a number of ophthalmic disorders that lead to blindness, including Diabetic Retinopathy. The collaboration grants NeuMedics full access to the MiDROPS™ formulation platform developed by EyeCRO, which can deliver drugs to the front and back of the eye via a topical eyedrop.

    Under the terms of the agreement, EyeCRO will receive a tiered single-digit royalty on commercialized products for ophthalmologic indications as well as a number of development and regulatory milestones. In exchange, NeuMedics will receive a license for exclusive rights to formulate their class of molecules utilizing the MiDROPS™ platform.

    “We look forward to developing this partnership with NeuMedics to further advance our MiDROPS™ platform into clinical trials”, said Rafal Farjo, Ph.D., Chief Operating Officer of EyeCRO.  Read the entire news release here.

    Dr. Rafal Farjo, EyeCRO LLC, NeuMedics

    NextPrevious
    • Disclaimer & Disclosure

    Oklahoma City Location

    840 Research Parkway, Suite 250
    OKC, OK 73104
    PHONE 405/235-2305

    Click HERE for directions.

    Tulsa Location

    618 E. Third Street, Suite 1
    Tulsa, OK 74120
    PHONE 918/582-5592

    Click HERE for directions.

    • Disclaimer & Disclosure
    Copyright 2021 i2E, Inc. | All Rights Reserved
    • About
    • Portfolio
    • Team
    • Funds
    i2E Management